Literature DB >> 1495353

Postoperative radiation therapy for cervical lymph node metastases from an occult squamous cell carcinoma.

C Maulard1, M Housset, P Brunel, J Huart, L Ucla, C Rozec, S Delanian, F Baillet.   

Abstract

One hundred thirteen patients with cervical metastases from a squamous cell carcinoma and no evidence of the primary tumor were treated for cure by surgery and routine large-field postoperative irradiation. Patients were staged according to the 1987 American Joint Committee on Cancer (AJCC) classification. There were 24 N1, 54 N2, 29 N3, and 6 Nx lesions. One hundred four patients underwent cervical lymph node dissection and 9 had adenectomy. All patients received postoperative external beam therapy to the entire naso-oro-pharyngo-larynx and all cervical lymphatics. The overall nodal failure rate was 13.7%. Nodal failure was significantly correlated with N staging (P = .01) and with the number of histologically involved nodes (P = .05). NOdal failure was 21% when nodes were initially fixed versus 7.5% when they were not (P = .07) and 18% when there was extracapsular spread versus 4.3% when the capsule was intact (P = .11). Eleven patients (9.7%) developed a subsequent primary lesion. In 3 patients (2.6%), this primary was located in the previously irradiated area and, in 2 cases, under the anterior block of lateral fields. Metastases occurred in 18 patients (16%). The five-year overall survival rate was 38%. Survival was correlated with N staging (P less than .02), nodal fixation (P = .05), extracapsular spread (P = .01) and loosely with the number of histologically involved nodes (P = .08). On the contrary, histological differentiation did not influence the local control rate, nor the development of metastases or subsequent primary lesions. Large-field prophylactic radiation therapy appears to be effective in preventing the emergence of initially occult primary lesions. However, control of disease in the neck and survival remain disappointing in patients with advanced nodal disease, even after combined surgery and radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1495353     DOI: 10.1288/00005537-199208000-00007

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  7 in total

1.  Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database.

Authors:  Huaising C Ko; Shuai Chen; Aaron M Wieland; Menggang Yu; Andrew M Baschnagel; Gregory K Hartig; Paul M Harari; Matthew E Witek
Journal:  Head Neck       Date:  2017-07-24       Impact factor: 3.147

Review 2.  Diagnosis and management of neck metastases from an unknown primary.

Authors:  L Calabrese; B A Jereczek-Fossa; J Jassem; A Rocca; R Bruschini; R Orecchia; F Chiesa
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-02       Impact factor: 2.124

3.  Long-term results of radio(chemo)therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival.

Authors:  Miloslav Pala; Pavla Novakova; Zdena Pechacova; Lucie Vesela; Antonin Vrana; Jarmila Sukova; Petra Holeckova; Tereza Drbohlavova; Tomas Podlesak; Lubos Petruzelka
Journal:  Strahlenther Onkol       Date:  2022-08-09       Impact factor: 4.033

4.  Cervical metastasis from the unknown primary tumor.

Authors:  A L Oen; M F de Boer; W C Hop; P Knegt
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

Review 5.  Occult primary head and neck carcinoma.

Authors:  Cecelia E Schmalbach; Frank R Miller
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

Review 6.  Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP.

Authors:  Nicholas Pavlidis; George Pentheroudakis; George Plataniotis
Journal:  Clin Transl Oncol       Date:  2009-06       Impact factor: 3.405

Review 7.  Cervical lymph node metastases from occult squamous cell carcinoma.

Authors:  Carsten Nieder; K Kian Ang
Journal:  Curr Treat Options Oncol       Date:  2002-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.